First-line fadrozole HCI (CGS 16949A) versus tamoxifen postmenopausal women with advanced breast cancer

Annals of Oncology

Volumn 7, Issue 5, 1996, Pages 471-479

  Thurlimann B ^a   Beretta, K ^b   Bacchi, M ^c   Castiglione Gertsch, M ^c   Goldhirsch, A ^b   Jungi, W F ^a   Cavalli, F ^b   Senn, H J ^a   Fey, M ^c   Lohnert T ^c  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aromatase inhibitor; Breast cancer; CGS 16949A; Fadrozole; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; FADROZOLE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOT FLUSH; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0038478620     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010635     Document Type: Article

References (26)

1. Levi F, La Vecchia C, Lucchini F, Randimbison L. Epidemiology of Cancer in Switzerland. Lausanne, Switzerland, Association of Swiss Cancer Registries 1994.
2. Early Breast Cancer Trialist Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy: 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
3. Henderson IC. Endocrine therapy of metastatic breast cancer. In Harris JR, Hellmann S, Henderson IC et al. (eds): Breast Diseases. Philadelphia, PA: Lippincott Publishers 1991; 559-603.
4. Paterson AHG, Hanson J, Pritchard KI et al. Comparison of antiestrogen and progestogen. Therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 1990; 17 (Suppl 9): 52-67.
5. Smith J, Harris AL, Morgan M et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomised cross over trial. BMJ 1991; 283: 1432-4.
6. Muss BH, Case LD, Atkins JN et al. Tamoxifen versus high dose medroxyprogesterone acetate as an initial endocrine therapy for patients with metastatic breast cancer. Piedmont Association Study. J Clin Oncol 1994; 12: 1630-8.
7. Gale KE, Anderson JW, Tormey DC et al. Hormonal treatment for metastatic breast cancer an Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73(2): 354-61.
8. Poortman J, Thijssen JHH, Schwarz F. Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. J Clin Endocrinol Metab 1973; 37: 101-9.
9. Fishman J. Biochemical mechanism of aromatization. Cancer Res 1982; 42 (Suppl): 3277S-3280S.
10. Nimrod A, Ryan K. Aromatization of androgens by human abdominal and breast fat tissue. J Clin Endocrinol Metab 1975; 40: 362-72.
11. Schteingrad GE, Cash R, Conn JW. Aminoglutethimide and metastatic adrenal cancer. J Am Med Assoc 1966; 198: 1007-10.
12. Gale KE. Treatment of advanced breast cancer with aminoglutethimide: A 14-year experience. Cancer Res 1982; 42 (Suppl): 3389S-3396S.
13. Harvey HA, Lipton A, Santen RJ et al. Clinical trial with the aromatase inhibitors CGS 16949A in advanced breast cancer. Preliminary results. In Jonat W, Santen RJ (eds): Aromatase Inhibition Present and Future. Symposium 15th UICC International Cancer Kongress Hamburg. New Jersey: Parthenon Publishing Group 1991; 89-96.
14. Beretta KR, Höffken K, Kvinnsland S et al. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer - a phase I study. Ann Oncol 1990; 1: 421-6.
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975; 31: 103-15.
16. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization 1979.
17. StatXact. Statistical Software for Exact Nonparametric Inference. User Manual Version 2. Cambridge MA: Cytel Corporation.
18. Cox DR, Snell EJ. Analysis of Binary Data. Second ed. London: Chapman and Hall 1988.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-81.
20. Cox DR. Regression models and life tables. J R Statist Soc B 1972; 34: 187-220.
21. Thürlimann B, Beretta K, Bacchi M et al. First line fadrozole HCI (CGS 16949A) versus tamoxifen in advanced breast cancer: Prospective randomised Study SAKK 20/88. Proc ASCO 1995; 14: 98 (Abstr 90).
22. Petru E, Schmahl D. On the role of additive hormon monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide in advanced breast cancer. Klin Wochenschr 1978; 65: 959-66.
23. Raats J, Falkson HC, Falkson CI. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 1992; 10(1): 111-6.
24. Höffken K, Chacon R, Dombernowsky P et al. Fadrozole hydrocloride (CGS 16949A). Double blind dose-finding study in postmenopausal patients with advanced breast cancer. Ann Oncol 1992; 3 (Suppl 5): 76 (Abstr 294).
25. Harvey HA, Lipton A, White DS. Crossover comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 1982; 42 (Suppl 8): 3451S-3453S.
26. Perez Carrion R, Alberola Clandel V, Clandel V et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5 (Suppl 7): 519-24.